These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33289956)

  • 1. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
    Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
    Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
    Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Lisyanskaya AS; Makhson AN; Rolski J; Gorbounova VA; Ghatage P; Bidzinski M; Shen K; Ngan HY; Vergote IB; Nam JH; Park YC; Lebedinsky CA; Poveda AM
    J Clin Oncol; 2010 Jul; 28(19):3107-14. PubMed ID: 20516432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
    Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
    Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
    Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.
    Nicoletto MO; Baldoni A; Casarin A; Randon G; Nardin M; Baretta Z; Lardelli P; Nieto A; Alfaro V; Rigamonti C; Conte PF
    Tumori; 2015; 101(5):506-10. PubMed ID: 26108247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
    Poveda A; Vergote I; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Kaye SB; Colombo N; Lebedinsky C; Parekh T; Gómez J; Park YC; Alfaro V; Monk BJ
    Ann Oncol; 2011 Jan; 22(1):39-48. PubMed ID: 20643862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
    Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
    Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
    Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
    Sehouli J; Alfaro V; González-Martín A
    Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
    Wang T; Tang J; Yang H; Yin R; Zhang J; Zhou Q; Liu Z; Cao L; Li L; Huang Y; Jiang K; Wang W; She F; Guan N; Hou Z; Li N; Wu L
    JAMA Oncol; 2022 Aug; 8(8):1169-1176. PubMed ID: 35771546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
    Marth C
    Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
    Perez-Fidalgo JA; Cortés A; Guerra E; García Y; Iglesias M; Bohn Sarmiento U; Calvo García E; Manso Sánchez L; Santaballa A; Oaknin A; Redondo A; Rubio MJ; González-Martín A
    ESMO Open; 2021 Aug; 6(4):100212. PubMed ID: 34329939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
    Vertechy L; Boccia SM; Tiberi G; Avesani G; Corrado G; Fagotti A; Scambia G; Marchetti C
    Int J Gynecol Cancer; 2023 Feb; 33(2):243-249. PubMed ID: 36564097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world experience with trabectedin for the treatment of recurrent ovarian cancer.
    Romero I; López-Guerrero JA; Pignata S
    Expert Rev Anticancer Ther; 2021 Oct; 21(10):1089-1095. PubMed ID: 34128757
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
    Alberts DS; Liu PY; Wilczynski SP; Clouser MC; Lopez AM; Michelin DP; Lanzotti VJ; Markman M;
    Gynecol Oncol; 2008 Jan; 108(1):90-4. PubMed ID: 17949799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.